(NASDAQ: VIR) Vir Biotechnology's forecast annual revenue growth rate of -2.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Vir Biotechnology's revenue in 2025 is $19,000,000.On average, 11 Wall Street analysts forecast VIR's revenue for 2025 to be $1,546,278,738, with the lowest VIR revenue forecast at $639,849,058, and the highest VIR revenue forecast at $5,396,903,150. On average, 11 Wall Street analysts forecast VIR's revenue for 2026 to be $1,782,019,913, with the lowest VIR revenue forecast at $408,414,292, and the highest VIR revenue forecast at $4,324,885,091.
In 2027, VIR is forecast to generate $2,538,558,769 in revenue, with the lowest revenue forecast at $408,414,292 and the highest revenue forecast at $5,571,937,847.